奥希替尼和铂类化疗进展后转移性 EGFR 突变型非小细胞肺癌患者的现有和新兴治疗选择：播客讨论。
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.
机构信息
University of California San Diego, La Jolla, San Diego, CA, 92093, USA.
Northwestern University, Chicago, IL, 60611, USA.
出版信息
Adv Ther. 2023 Dec;40(12):5579-5590. doi: 10.1007/s12325-023-02680-1. Epub 2023 Oct 6.
Abstract
Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resistance. Platinum-based chemotherapy is the recommended treatment following progression with osimertinib but responses to platinum-based chemotherapy are transient. Salvage therapies, which are used after progression on platinum-based chemotherapy, have poor clinical outcomes in addition to substantial toxicity. In this podcast, we discuss the current treatment landscape and emerging therapeutic options for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following treatment with osimertinib and platinum-based chemotherapy.Podcast audio available for this article.
摘要
患有转移性表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）的患者广泛接受奥希替尼治疗，这是首选的一线治疗选择。然而，由于 EGFR 依赖性或 EGFR 非依赖性耐药机制的存在，疾病进展不可避免。奥希替尼治疗进展后，推荐使用铂类化疗，但铂类化疗的反应是短暂的。在铂类化疗进展后使用的挽救疗法除了具有较大的毒性外，临床结局也较差。在本期播客中，我们讨论了奥希替尼和铂类化疗治疗后疾病进展的转移性 EGFR 突变型 NSCLC 患者的当前治疗现状和新的治疗选择。本文提供播客音频。
相似文献
1
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.奥希替尼和铂类化疗进展后转移性 EGFR 突变型非小细胞肺癌患者的现有和新兴治疗选择：播客讨论。
Adv Ther. 2023 Dec;40(12):5579-5590. doi: 10.1007/s12325-023-02680-1. Epub 2023 Oct 6.
2
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.FDA 对奥希替尼治疗携带表皮生长因子受体 T790M 突变的转移性非小细胞肺癌的获益-风险评估。
Oncologist. 2018 Mar;23(3):353-359. doi: 10.1634/theoncologist.2017-0425. Epub 2017 Dec 14.
3
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.奥希替尼治疗日本 EGFR T790M 突变阳性的晚期非小细胞肺癌患者：AURA3 试验。
Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.
4
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.真实世界数据：奥希替尼和铂类化疗治疗 EGFR 突变型 NSCLC 耐药患者的疗效。
Adv Ther. 2023 Oct;40(10):4545-4560. doi: 10.1007/s12325-023-02616-9. Epub 2023 Aug 12.
5
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.奥希替尼对比含铂双药化疗用于 EGFR-TKI 治疗后进展的 EGFRm T790M NSCLC 患者的倾向性评分匹配调整的间接比较
Clin Drug Investig. 2018 Apr;38(4):319-331. doi: 10.1007/s40261-017-0611-3.
6
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.一项评估奥希替尼在 EGFR 突变阳性 NSCLC 患者中的疗效的 II 期研究（WJOG12819L），这些患者在接受第一代或第二代 EGFR TKI 和铂类化疗后发生系统性疾病（T790M 阴性）进展。
Lung Cancer. 2023 Mar;177:44-50. doi: 10.1016/j.lungcan.2023.01.011. Epub 2023 Jan 28.
7
Acquired Resistance to Osimertinib in -Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?奥希替尼耐药的 - 突变型非小细胞肺癌：我们如何克服它？
Int J Mol Sci. 2022 Jun 22;23(13):6936. doi: 10.3390/ijms23136936.
8
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).奥希替尼联合铂类加培美曲塞治疗表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌的II期研究：OPAL研究（NEJ032C/LOGIK1801）
Clin Lung Cancer. 2021 Mar;22(2):147-151. doi: 10.1016/j.cllc.2020.09.023. Epub 2020 Oct 16.
9
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.奥希替尼在中国表皮生长因子受体突变型晚期非小细胞肺癌二线治疗中的成本效果分析。
Clin Ther. 2019 Nov;41(11):2308-2320.e11. doi: 10.1016/j.clinthera.2019.09.008. Epub 2019 Oct 10.
10
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
引用本文的文献
1
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure.应对肺癌治疗中耐药性的复杂性：机制、类器官模型及克服治疗失败的策略
Cancers (Basel). 2024 Nov 28;16(23):3996. doi: 10.3390/cancers16233996.
2
Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review.接受新辅助治疗的非小细胞肺癌患者循环肿瘤DNA的价值、进展与挑战：一项叙述性综述
J Thorac Dis. 2024 Jul 30;16(7):4742-4755. doi: 10.21037/jtd-24-265. Epub 2024 Jul 4.
本文引用的文献
1
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.帕博利珠单抗联合培美曲塞和铂类对比培美曲塞和铂类用于治疗 EGFR/ALK 抑制剂耐药、突变的转移性非鳞状非小细胞肺癌的 III 期 KEYNOTE-789 研究
J Clin Oncol. 2024 Dec;42(34):4029-4039. doi: 10.1200/JCO.23.02747. Epub 2024 Aug 22.
2
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.BBT-176，一种新型第四代针对非小细胞肺癌奥希替尼耐药 EGFR 突变的酪氨酸激酶抑制剂。
Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901.
3
Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.美国社区肿瘤实践环境中转移性非鳞状非小细胞肺癌（NSCLC）患者的真实世界生物标志物检测模式。
Clin Lung Cancer. 2023 Jul;24(5):429-436. doi: 10.1016/j.cllc.2023.03.002. Epub 2023 Mar 20.
4
Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.美国转移性非鳞状非小细胞肺癌患者在标准治疗方案进展后的真实世界治疗模式及结局
Lung Cancer. 2023 May;179:107177. doi: 10.1016/j.lungcan.2023.107177. Epub 2023 Mar 20.
5
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. Epub 2023 Jan 23.
6
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.AURA3 试验中 EGFR 突变型晚期非小细胞肺癌患者奥希替尼获得性耐药机制分析。
Nat Commun. 2023 Feb 27;14(1):1071. doi: 10.1038/s41467-023-35962-x.
7
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择
Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.
8
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.奥希替尼治疗 EGFR 突变型非小细胞肺癌中枢神经系统转移：治疗策略的当前证据和未来展望。
Target Oncol. 2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7. Epub 2023 Jan 18.
9
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
10
Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer.非小细胞肺癌中的表皮生长因子受体突变与脑转移
Front Oncol. 2022 Nov 15;12:912505. doi: 10.3389/fonc.2022.912505. eCollection 2022.
Zotero 插件